# 1. Financial Performance ## A. Key Figures * **Q3 Consolidated Revenue:** **₹19,712 Mn** ($222M) (+35.7% INR, +29.1% CC) * **9M Revenue:** **₹51,686 Mn** ($591.8M) (+29.2% INR, +24.2% CC) · **Organic Growth:** +18% INR, +13.5% CC * **Q3 Adjusted EBITDA:** **₹500 Cr** ($7M) (+2% YoY) · **Margin:** 26% * **9M Adjusted EBITDA:** **₹13,164 Mn** (+25.3% YoY) * Adjusted PAT: ₹8,236M (+44.3% YoY) · Adjusted EPS (TTM): ₹2.27 (vs. ₹1.76 prior) * **Adjusted ROCE:** **~50%** (steady long-term) * **DSO:** **86 days** (51 days billed, 35 days unbilled) * **9M Cash Conversion:** **49.7%** ## B. Revenue Growth * **Strong Organic Momentum:** Revenue growth significantly outpaced reported figures on an organic basis, with robust demand and AEP season tailwinds driving performance. * **Seasonal Uptick:** Q3 revenues rose meaningfully from Q2, reflecting expected seasonal business patterns and project ramp-ups. * **Growth Mix Pressure:** Offshore and U.S. revenue mix weighed on profitability despite strong top-line expansion. ## C. Profitability Trends * **Stable Margins Amid Headwinds:** Adjusted EBITDA margin held firm at 26% despite less profitable geographic mix, supported by **100 bps from operating leverage** and **1% forex benefit**. * **Profit Growth Drivers:** Adjusted PAT expansion driven by higher operating profits, lower interest costs, and reduced amortisation charges. * **Labour Code Impact:** A one-time ₹80 Cr P&L impact recorded, with an ongoing **20 bps drag on margins** expected going forward. * **Productivity Offsets Pricing Pressure:** Management highlighted that client-driven margin pressures have been neutralized by technology-led transformation and efficiency gains. ## D. Balance Sheet Health * **Debt Reduction on Track:** Net debt continues to decline, with full repayment of current obligations expected by **FY2027**. * **M&A Strategy Intact:** Acquisitions remain a growth lever, funded entirely through internal accruals with no incremental debt. * **ROCE Over ROE:** Adjusted ROCE of **50%** is the preferred return metric, as high goodwill inflates equity and depresses reported ROE. ## E. Cash Flow Conversion * **Temporary Cash Conversion Dip:** Low 9M cash conversion of 7% attributed to **15% AR growth** from strong Q3 revenue and prior-year tax refunds. * **DSO Normalization Expected:** Elevated DSO of 86 days driven by **5% QoQ revenue growth** and higher unbilled receivables; expected to normalize in Q4. * **No Collection Concerns:** Management reiterated that receivables and DSO are within control, with no issues in collections or credit quality. --- # 2. Client & Segment Performance ## A. Key Figures * Revenue Growth: **37.3% YoY** Payer segment · **21.6% YoY** Provider segment * **Segment Revenue Contribution:** **90.4%** Payer · **9.6%** Provider * Top 10 Client Revenue Share: **84.6%** (down from 90.5% in FY25) * **New Logos (9M FY26):** **7 of 12** from mid/small market segment * **Active Clients (as of Dec 31, 2025):** **81** (3 new clients in Q3) * ACV (Q3): **$30.5 million** aggregate from new and existing clients * **Cannibalization Impact:** **150–200 bps** revenue headwind ## B. Payer & Provider Growth * **Sustained Momentum:** Payer and Provider segments delivered strong performance in Q3, driven by execution excellence and rising demand for transformation support amid regulatory change. * **Outperformance in Key Portfolios:** Membership growth exceeded forecasts, boosting activity in engagement services, prior authorization, claims, and clinical workflows. * **Trusted Partner Status:** Near-perfect forecast accuracy reinforces client trust and deepens strategic alignment, particularly with major payers. * **Clinical Services Expansion:** Clinical offerings represent a high-potential growth vector, with scaling underway for a large client and broader adoption expected. * **Cannibalization as Structural Factor:** Revenue offset of **150–200 bps** persists due to technology efficiencies and onshore-to-offshore delivery shifts, despite volume stability. ## C. Top Client Revenue * **High-Single-Digit Growth in Top Accounts:** Top 10 clients continue growing rapidly, tempering declines in concentration despite reduced reliance. * **Long-Term Client Stickiness:** Top five clients, with **18+ years** of tenure, grew at high-single-digit rates, underscoring durable relationships and expansion potential. * **Strategic Deal Focus:** Large managed services contracts are concentrated in top clients, expected to sustain strong growth through FY26. ## D. New Logo Additions * **Mid/Small Market Traction:** Majority of new logos in 9M FY26 came from mid and small markets, validating diversification strategy. * **Recent Wins Include Marquee Names:** Q3 additions included a **top 10 health insurer**, benefit administrator, and regional plan, enhancing client quality. * **Inorganic Leverage Accelerating Reach:** DCI acquisition expands payment integrity capabilities, unlocking new client segments and solution breadth. * **BroadPath Integration Timeline:** Contribution to organic growth begins in **Q1 next fiscal**, with synergy realization expected over 2–3 years. ## E. ACV Trends * **ACV Volatility Expected:** Net new ACV dipped slightly QoQ due to **lumpiness** in large managed services deals, not operational performance. * **Seasonal Pressure Acknowledged:** AP season temporarily slowed deal progression, contributing to marginal ACV softness; recovery anticipated. * **Forward Confidence Maintained:** Despite near-term fluctuations, management expects ACV to trend upward in coming quarters. --- # 3. Demand & Outsourcing Trends ## A. Key Figures * **OE Seasonal Revenue Contribution:** **5.5%** of annual revenue FY2026 (up from 3%) * **Q3 Revenue Growth:** **17%** over Q2 (seasonal and acquisition-driven) * **Outsourcing Penetration in Top Clients:** **50–60%** (vs. industry avg. of 20%) ## B. AEP/OE Season Impact * **Stronger-Than-Expected OE Performance:** Open enrollment results exceeded expectations, driven by robust organic execution and integration of BroadPath, contributing meaningfully to Q3 growth. * **Favorable Payer Priorities:** 2026 AEP season aligned with payer focus on margin repair and STARs performance, boosting demand for care coordination and member experience services. * **Regulatory Clarity, No Near-Term Risk:** Proposed CMS 2027 changes do not impact 2026 membership or reimbursement; risk-adjusted rates expected to be flat or down ~2% in CY2027. * **Seasonal Ramp-Down Expected:** Elevated OE activity is temporary, with revenue normalization anticipated in Q4, consistent with historical patterns. ## C. Outcome-Based Shift * **Strategic Pivot to Outcome-Based Models:** Accelerating client traction in managed services with committed cost reductions over 3–5 years, enhancing differentiation vs. labor-arbitrage vendors. * **Technology-Integrated Offerings:** New outcome-based solutions combine end-to-end services with platform partnerships, eliminating client license fees and improving margin resilience. * **Pipeline Expansion:** Multiple new outcome-based offerings set for launch in the next 2–3 quarters, targeting improved close rates and sustained FY2027+ growth. ## D. White Space Expansion * **High Penetration, Continued Upside:** Despite top clients already outsourced 50–60% of eligible work, white space remains in upstream/downstream tasks and new service lines like HEDIS abstraction. * **Domain-Led Growth Engine:** Recent large clinical win from a top-five client underscores persistent expansion potential within mature accounts via bundled, end-to-end solutions. * **Emerging Regulatory Tailwinds:** Increased scrutiny on PBMs and drug pricing is fueling demand for clinical accountability and policy support—new avenues for growth. ## E. Cross-Sell Pipeline * **Cross-Sell Pause, Not Slowdown:** No activity in Q3 due to AEP season, but **at least a dozen** cross-sell opportunities now active with near-term closure expectations. * **Consolidation Trend:** Clients moving from fragmented outsourcing to integrated, value-driven contracts, enabling penetration gains and pricing model evolution. --- # 4. Geography & Delivery Mix ## A. Key Figures * **Delivery Mix Impact:** **220 bps** negative impact (geographic shift) · **20 bps** QoQ margin decline * **Global Workforce:** **48,522 employees** across five countries * Attrition Rate: 22.8% for the quarter (steady) ## B. Onshore vs Offshore * **Margin Pressure from Mix Shift:** Delivery mix deterioration driven by strong seasonal and organic growth in **lower-margin geographies** (U.S., Philippines, Jamaica), weighing on overall margins despite higher volumes. * **Offshoring Opportunity:** Clients continue to evaluate shifting onshore work to offshore locations, particularly when outsourced providers offer greater efficiency. ## C. Global Workforce * **Scaled Capacity:** Headcount expansion supports ramp-up in AEP and payer/provider operations, reinforcing delivery scalability and global footprint. --- # 5. Technology & Service Innovation ## A. Key Figures * **AI-Driven Use Cases:** **32** deployed across **10 clients** * **Tech & Transformation Team:** **Over 400 employees** focused on GenAI and efficiency initiatives ## B. GenAI Use Cases * **Strategic Positioning:** Advancing large-scale, multiyear managed transformations by combining domain-led operations with **technology-enabled solutions**, underpinned by growing GenAI adoption in production environments. * **Growth & Margin Catalyst:** GenAI is enabling **higher cost takeouts**, **new client engagements**, and **margin improvement potential**, increasingly embedded in outcome-based and gain-share service models. * **Workforce Development:** Ongoing investments in **AI-powered learning** are building future-ready capabilities in healthcare and technology domains. * **Client Demand Tailwinds:** Rising client expectations for GenAI-driven efficiency gains are strengthening competitive positioning and deal momentum. ## C. Synchrony Launch * **Integrated Solution Rollout:** Launched **Sagility Synchrony**—an end-to-end platform for Medicare Advantage operations—enhancing time to market, compliance, and member experience for clients. * **Commercial Execution:** Driving adoption post-launch through client consulting on **administrative and clinical cost optimisation**, with early traction in payer and BroadPath cross-sell opportunities. ## D. Automation Gains * **Third-Party Validation:** Recognized as an **innovator in revenue cycle management transformation** by Avasant RadarView 2025, citing scalable tech-enabled services and outcome-led delivery. * **Operational Leverage:** Anticipating higher throughput in **prior authorization, claims, and clinical workflows** due to payer cost pressures and rising service demand. * **Ecosystem Collaboration:** Expanding transformation capabilities through partnerships with technology platforms to deliver repeatable, scalable solutions. --- # 6. Client & Pricing Risks ## A. Margin Pressure * **Persistent Pricing Headwinds:** Pricing pressure remains a structural challenge across new and renewal contracts, with clients demanding greater value or rate reductions amid profitability concerns. * **Growth Despite Margin Pressure:** Company maintains expansion in large accounts by broadening service scope beyond traditional outsourcing, supporting revenue resilience. * **Peak Margin Vulnerability:** Current margins are at elevated levels versus peers, raising sustainability questions under ongoing client-driven cost and pricing pressures. * **Margin Protection Strategy:** Focus on **automation**, **productivity gains**, and **delivery quality** to safeguard profitability without sacrificing client retention. ## B. Cost Takeout Demands * **Demand Tailwinds from Client Cost Pressures:** Insurer cost challenges are accelerating outsourcing demand, particularly for administrative and clinical cost reduction, creating growth opportunities. * **Transformation-Led Value Delivery:** Company leverages technology and process transformation to deliver **committed cost savings** for clients while protecting its own margin structure. ## C. ACA Enrollment Risk * **Negligible ACA Exposure:** Company is insulated from recent **4% provisional ACA enrollment decline** due to subsidy expirations, with minimal business impact expected. --- # 7. Guidance & Outlook ## A. Key Figures * FY 2026 Revenue Guidance: 22.5% constant currency (raised from 21%+) · 13.8% organic growth * **EBITDA Margin Guidance:** **25%** adjusted (unchanged for FY 2026) · **24%** medium-term target maintained ## B. FY 2026 Revenue View * **Guidance Rebound:** Upward revision in full-year revenue outlook reflects strong AEP season performance and broad-based demand from existing clients and new logos. * **Growth Composition:** Revenue acceleration driven primarily by **increased outsourcing penetration**, not major wallet share gains, signaling structural market shift. * **Cash Flow Dynamics:** DSO expected to normalize by end of Q4 despite current pressure from unbilled revenue impacting year-to-date conversion. * **M&A Posture:** Strategic focus on acquisitions remains intact; pipeline active but deal execution contingent on **right opportunity at right valuation**, with potential outsourcing implications. ## C. EBITDA Margin Forecast * **Margin Resilience:** Full-year adjusted EBITDA margin guidance held at 25% despite cost and operational pressures, reflecting disciplined cost management. * **Forward View:** Planned rate changes delayed until 2027; current margin stability not influenced by future pricing actions. * **Medium-Term Framework:** 24% EBITDA margin target remains baseline for FY 2027, with updated guidance expected by quarter-end. ## D. Long-Term Growth Target * **Sustainable Growth Trajectory:** Long-term organic growth outlook remains in **low-to-mid teens**, supported by expansion into white spaces within existing accounts. * **Cannibalization Factored In:** Stated growth targets are net of expected **rising cannibalization**, indicating conservative and resilient planning assumptions. * **Dual-Engine Strategy:** Inorganic growth via acquisitions expected to supplement organic momentum, reinforcing multi-year expansion blueprint.